Frontiers in Microbiology
Cure8 research brief
Why This Matters
The paper summarizes the global research landscape on fecal microbiota transplantation (FMT) for IBD across major databases, showing growing focus on strain-level microbiome science and biosafety.
That matters because it highlights where research is headed and what gaps remain before FMT becomes a standardized, precision therapy for IBD.
Who Should Pay Attention
Researchers studying the microbiome or FMT, clinicians interested in IBD experimental therapies, and research-minded patients following FMT science.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article is a bibliometric and knowledge-mapping analysis of fecal microbiota transplantation (FMT) research for inflammatory bowel disease (IBD), using Web of Science Core Collection as the primary dataset and Scopus and PubMed as comparators. It maps publication growth, geographic and journal contributions, shifts in cited knowledge (from C.
difficile procedural work toward IBD trials, biosafety, formulations, and mechanistic microbiome–immune–metabolic research), and recommends priorities such as functional multi-omics, reproducible pipelines, donor–recipient matching, and biosafety surveillance.
The study analyzes indexed literature (2000–2025) rather than reporting new clinical trial data or treatment outcomes. It highlights how recent research emphasizes strain-level, function-oriented approaches and biosafety in FMT for IBD, but it does not claim that precision microbiome interventions have been achieved.
If you’re looking for practical treatment guidance (who should receive FMT, how it’s performed, or clinical effectiveness), this paper won’t provide direct clinical recommendations; it summarizes research trends and gaps instead.
Keep In Mind
This is a bibliometric analysis of published records (2000–2025) not a clinical trial or systematic review of patient outcomes. Findings reflect publication and citation patterns in indexed literature and should not be interpreted as direct evidence of clinical effectiveness.
The article itself notes that the mapped patterns do not demonstrate that precision microbiome intervention has been achieved.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Microbiology
PublisherFrontiers Media SA
AuthorsZheng Liu, Weijiu Mo, Jingrong Liang +16 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedNov 4, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Guangxi Natural Science Foundation
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Inflammatory Bowel Disease: From Multifactorial and Metabolic Pathogenesis to Systemic Disease and Precision Medicine
This review reframes IBD as a systemic disease influenced by gut microbes, metabolism, and immune interactions — which matters because it points toward better ways to stratify patients, monitor disease, and personalize...
PPARγ signaling pathway: strategies and limitations of natural compounds in the treatment of ulcerative colitis
The review identifies PPARγ as a key molecular hub in ulcerative colitis and compiles preclinical evidence that natural compounds can modulate PPARγ-related networks—suggesting possible new therapeutic directions that...
Ferulic acid - A promising candidate molecule for the treatment of colitis.
People with ulcerative colitis may be interested because ferulic acid is a plant-derived compound that, in lab and animal studies, appears to reduce gut inflammation, support the intestinal barrier, and positively...